Literature DB >> 21245128

Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis.

Takahiro Kuragano1, Katsukiyo Itoh, Yasushi Shimonaka, Aritoshi Kida, Minoru Furuta, Rie Kitamura, Mana Yahiro, Masayohi Nanami, Yoshinaga Otaki, Yukiko Hasuike, Hiroshi Nonoguchi, Takeshi Nakanishi.   

Abstract

BACKGROUND: Dysregulated iron metabolism has been suspected to be linked to anemia of chronic disease and to cardiovascular disease (CVD). For the purpose of clarifying the factors affecting arterial stiffness, we evaluated the relationship between iron metabolism, brachial-ankle (ba)-pulse wave velocity (PWV) and several risk factors for CVD in maintenance hemodialysis (MHD) patients.
METHODS: A total of 168 MHD patients were recruited, and the levels of iron parameters, hepcidin, CVD risk factors and ba-PWV were evaluated. The level of serum hepcidin-25 was specifically measured by liquid chromatography-tandem mass spectrometry.
RESULTS: Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and hepcidin were higher in MHD patients, which was consistent with results from our previous study. ba-PWV significantly correlated with age (P < 0.01, R = 0.34), total cholesterol (T-CHO; P = 0.02, R = 0.21), TNF-α (P < 0.01, R = 0.24) and hepcidin (P < 0.01, R = 0.25) but not with other iron parameters and CVD risk factors. According to multiple regression analysis, age (β = 0.30), T-CHO (β = 0.24) TNF-α (β = 0.19) and hepcidin (β = 0.23) were selected as the significant predictors of ba-PWV in MHD patients.
CONCLUSION: Serum levels of both hepcidin and TNF-α are independently associated with arterial stiffness in MHD patients, suggesting that microinflammation and iron metabolism might affect the integrity of arterial walls.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245128     DOI: 10.1093/ndt/gfq760

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

Review 1.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

Review 2.  In-depth review: is hepcidin a marker for the heart and the kidney?

Authors:  Rengin Elsurer Afsar; Mehmet Kanbay; Avsin Ibis; Baris Afsar
Journal:  Mol Cell Biochem       Date:  2021-05-04       Impact factor: 3.396

3.  Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients.

Authors:  Sena Memnune Ulu; Seref Yuksel; Atila Altuntaş; Emre Kacar; Ahmet Ahsen; Abdullah Altug; Sefa Celik; M Tugrul Sezer
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

Review 4.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 5.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

6.  A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?

Authors:  Nicola Tessitore; Albino Poli; Valeria Bedogna; Luca Corazza; Natascia Campostrini; Mauro Atti; Luisa Sereni; Annalisa Castagna; Domenico Girelli; Giuseppina Pessolano; Antonio Lupo
Journal:  J Nephrol       Date:  2017-03-28       Impact factor: 3.902

Review 7.  Iron and atherosclerosis: nailing down a novel target with magnetic resonance.

Authors:  Travis P Sharkey-Toppen; Arun K Tewari; Subha V Raman
Journal:  J Cardiovasc Transl Res       Date:  2014-03-04       Impact factor: 4.132

8.  The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.

Authors:  Serena Pelusi; Domenico Girelli; Raffaela Rametta; Natascia Campostrini; Carlo Alfieri; Michela Traglia; Paola Dongiovanni; Giovanna Como; Daniela Toniolo; Clara Camaschella; Piergiorgio Messa; Silvia Fargion; Luca Valenti
Journal:  BMC Nephrol       Date:  2013-02-22       Impact factor: 2.388

9.  Erythropoiesis-independent effects of iron in chronic kidney disease.

Authors:  Edwin Patino; Oleh Akchurin
Journal:  Pediatr Nephrol       Date:  2021-07-09       Impact factor: 3.651

10.  Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension.

Authors:  Luca Valenti; Alessandro Maloberti; Stefano Signorini; Marta Milano; Francesca Cesana; Fabrizio Cappellini; Paola Dongiovanni; Marianna Porzio; Francesco Soriano; Maura Brambilla; Giancarlo Cesana; Paolo Brambilla; Cristina Giannattasio; Silvia Fargion
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.